Also trades as: GLENMARK.BO (BSE) · $vol 1M
GLENMARK.NS NSE
Glenmark Pharmaceuticals Limited
1W: -4.1%
1M: -5.6%
3M: +5.4%
YTD: +19.1%
1Y: +15.0%
3Y: +187.3%
5Y: +302.6%
₹2,326.10 ($24.17)
-4.90 (-0.21%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$199.1B
+24.0% ▲
5Y CAGR: +5.0%
Total Liabilities
$94.0B
+30.5% ▲
5Y CAGR: +1.9%
Shareholders Equity
$105.1B
+18.8% ▲
5Y CAGR: +8.3%
Cash & Investments
$11.9B
-30.8% ▼
5Y CAGR: +0.6%
Total Debt
$5.9B
-76.0% ▼
5Y CAGR: -34.7%
Net Debt
-$5.8B
-173.1% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $14.1B | $11.6B | $16.6B | $17.1B | $11.8B |
| Short-Term Investments | $57M | $91M | $58M | $63M | $89M |
| Cash & ST Investments | $14.4B | $11.7B | $16.6B | $17.1B | $11.9B |
| Net Receivables | $31.0B | $32.5B | $18.6B | $41.8B | $49.6B |
| Inventory | $25.0B | $23.7B | $25.1B | $32.8B | $34.3B |
| Other Current Assets | $10.2B | $32.9B | $13.7B | $164M | $17.2B |
| Total Current Assets | $82.8B | $107.3B | $74.3B | $93.0B | $113.0B |
| Property, Plant & Equip. | $46.5B | $42.2B | $35.4B | $38.6B | $43.2B |
| Goodwill & Intangibles | $22.9B | $24.2B | $13.3B | $14.6B | $25.1B |
| Long-Term Investments | $557M | $473M | $8.0B | $605M | $2.1B |
| Other Non-Current Assets | $1.2B | $1.6B | $2.1B | $2.5B | $3.3B |
| Total Non-Current Assets | $88.0B | $86.5B | $69.3B | $67.5B | $86.1B |
| Total Assets | $170.8B | $193.7B | $143.6B | $160.5B | $199.1B |
| — Liabilities — | |||||
| Accounts Payable | $22.9B | $20.0B | $25.4B | $25.8B | $37.4B |
| Short-Term Debt | $11.0B | $5.0B | $9.9B | $16.8B | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $9.6B | $21.6B | $16.4B | $15.9B | $24.3B |
| Total Current Liabilities | $46.9B | $51.1B | $58.2B | $59.7B | $63.8B |
| Long-Term Debt | $25.7B | $38.5B | $0 | $5.1B | $0 |
| Other Non-Current Liab. | $312M | $2.7B | $5.4B | $4.8B | $16.5B |
| Total Non-Current Liabilities | $29.6B | $44.3B | $6.9B | $12.3B | $30.2B |
| Total Liabilities | $76.5B | $95.3B | $65.1B | $72.0B | $94.0B |
| — Equity — | |||||
| Common Stock | $282M | $282M | $282M | $282M | $282M |
| Retained Earnings | $92.1B | $94.6B | $80.2B | $88.0B | $98.8B |
| Accumulated OCI | -$18.4B | -$17.0B | -$17.4B | -$16.6B | -$10.9B |
| Total Stockholders Equity | $90.9B | $94.7B | $78.5B | $88.5B | $105.1B |
| Total Liabilities & Equity | $170.8B | $193.7B | $143.6B | $160.5B | $199.1B |
| — Key Metrics — | |||||
| Total Debt | $39.6B | $46.1B | $12.3B | $24.7B | $5.9B |
| Net Debt | $25.5B | $34.5B | -$4.3B | $8.0B | -$5.8B |
| Total Investments | $614M | $563M | $8.0B | $668M | $2.2B |